Innate Pharma (IPHA) Net Cash Flow (2019 - 2024)
Historic Net Cash Flow for Innate Pharma (IPHA) over the last 6 years, with Q4 2024 value amounting to -$13.8 million.
- Innate Pharma's Net Cash Flow rose 6287.93% to -$13.8 million in Q4 2024 from the same period last year, while for Jun 2025 it was -$50.9 million, marking a year-over-year increase of 1301.12%. This contributed to the annual value of -$4.0 million for FY2024, which is 7332.76% up from last year.
- As of Q4 2024, Innate Pharma's Net Cash Flow stood at -$13.8 million, which was up 6287.93% from -$37.1 million recorded in Q4 2023.
- Innate Pharma's 5-year Net Cash Flow high stood at -$13.8 million for Q4 2024, and its period low was -$79.1 million during Q4 2020.
- In the last 5 years, Innate Pharma's Net Cash Flow had a median value of -$37.1 million in 2023 and averaged -$43.9 million.
- Its Net Cash Flow has fluctuated over the past 5 years, first surged by 6848.18% in 2022, then crashed by 7351.97% in 2023.
- Quarter analysis of 5 years shows Innate Pharma's Net Cash Flow stood at -$79.1 million in 2020, then grew by 14.09% to -$67.9 million in 2021, then surged by 68.48% to -$21.4 million in 2022, then tumbled by 73.52% to -$37.1 million in 2023, then surged by 62.88% to -$13.8 million in 2024.
- Its Net Cash Flow was -$13.8 million in Q4 2024, compared to -$37.1 million in Q4 2023 and -$21.4 million in Q4 2022.